Antineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantAntineoplastic AgentsCombined Modality TherapyCisplatinChemoradiotherapyNeoadjuvant TherapyBreast NeoplasmsTreatment OutcomeRectal NeoplasmsRadiotherapy, AdjuvantCell Line, TumorDoxorubicinNeoplasmsNeoplasm StagingAdenocarcinomaLung NeoplasmsDrug Resistance, NeoplasmChemoradiotherapy, AdjuvantDisease-Free SurvivalSurvival AnalysisRadiation InjuriesRadiotherapyRadiation, IonizingSurvival RateRadiation DosageRadiotherapy DosagePrognosisApoptosisCarcinoma, Squamous CellPancreatic NeoplasmsPaclitaxelDrug Screening Assays, AntitumorCyclophosphamideDeoxycytidineAntimetabolites, AntineoplasticEtoposideAntineoplastic Agents, PhytogenicFluorouracilRadiation ToleranceGene Expression Regulation, NeoplasticNeoplasm Recurrence, LocalHead and Neck NeoplasmsTumor Cells, CulturedDose-Response Relationship, RadiationEsophageal NeoplasmsMice, NudeOvarian NeoplasmsNeoplasm MetastasisDrug Administration ScheduleCell ProliferationCell SurvivalColonic NeoplasmsCarboplatinCarcinoma, Non-Small-Cell LungStomach NeoplasmsOrganoplatinum CompoundsFollow-Up StudiesTaxoidsXenograft Model Antitumor AssaysVinblastineNeoplasm InvasivenessAntibiotics, AntineoplasticEsophagectomyInduction ChemotherapyRadiation-Sensitizing AgentsDose-Response Relationship, DrugTime FactorsCarcinomaRadiationMethotrexateCamptothecinDose FractionationTumor Markers, BiologicalMitomycinProspective StudiesKaplan-Meier EstimateUterine Cervical NeoplasmsClinical Trials as TopicColorectal NeoplasmsNeoplasm ProteinsPreoperative CareCell CycleRadiation ProtectionBrain NeoplasmsTumor Suppressor Protein p53BleomycinAntineoplastic Agents, AlkylatingRNA, Small InterferingDisease ProgressionPancreaticoduodenectomyRadiation MonitoringTumor BurdenDrug Delivery SystemsDrug SynergismNeoplasm TransplantationBlotting, WesternSignal TransductionAnthracyclinesAntibodies, Monoclonal, Humanized